NASDAQ:NLTX Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis $26.47 +0.82 (+3.20%) As of 10/5/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC Filings About Neoleukin Therapeutics Stock (NASDAQ:NLTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neoleukin Therapeutics alerts:Sign Up Key Stats Today's Range$24.87▼$26.7650-Day Range$25.65▼$40.8452-Week Range$2.03▼$14.36Volume211,773 shsAverage Volume50,104 shsMarket Capitalization$248.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Neoleukin Therapeutics, Inc. was a biotechnology company focused on developing computationally designed immunotherapies for cancer and other serious diseases. The company used protein-engineering and computational-design technologies to create novel cytokine-based medicines intended to activate the immune system against tumors while potentially reducing some of the limitations associated with naturally occurring cytokines. Neoleukin’s lead investigational product was NL-201, a designed cytokine mimetic intended to selectively stimulate signaling pathways associated with interleukin-2 and interleukin-15. The therapy was evaluated in early-stage clinical studies for advanced solid tumors and hematologic malignancies. The company also maintained a broader research pipeline based on its de novo protein-design platform. The company was headquartered in Seattle, Washington, and its programs were developed for potential use in international oncology markets. Neoleukin was formed through the 2019 transformation of Aquinox Pharmaceuticals and was led during its development period by biotechnology executive Jonathan Lim, M.D. In 2022, Neoleukin announced plans to discontinue development of NL-201 and wind down its operations, ending its activities as an operating biotechnology company.AI Generated. May Contain Errors. Read More Receive NLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NLTX Stock News HeadlinesIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 20, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 14, 2023 | finance.yahoo.comFDA Clears This Under-$5 Biotech for Phase 2 Clinical TrialA NASDAQ-listed biotech just cleared a major regulatory milestone. The FDA has cleared its lead multiple sclerosis therapy, Lucid-MS, to enter Phase 2 clinical trials - the first time it will be tested in patients with progressive MS. Unlike treatments that suppress the immune system, Lucid-MS is designed to protect myelin, the insulating layer destroyed by the disease. In a pre-clinical mouse model, treatment led to movement recovery including walking. Independent research projects peak annual sales of up to $5 billion if Phase 2 succeeds. The stock still trades under $5 per share.October 6 at 1:00 AM | The Tomorrow Investor (Ad)Neoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesDecember 4, 2023 | benzinga.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…October 5, 2023 | markets.businessinsider.comNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 26, 2023 | finanznachrichten.deNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comNeoleukin Therapeutics Recent Insider ActivityAugust 18, 2023 | benzinga.comSee More Headlines NLTX Stock Analysis - Frequently Asked Questions How have NLTX shares performed this year? Neoleukin Therapeutics' stock was trading at $22.11 on January 1st, 2026. Since then, NLTX shares have increased by 16.0% and is now trading at $25.65. How were Neoleukin Therapeutics' earnings last quarter? Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($5.60) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($5.60). When did Neoleukin Therapeutics' stock split? Neoleukin Therapeutics's stock reverse split on Tuesday, December 19th 2023.The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of Neoleukin Therapeutics? Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neoleukin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neoleukin Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE) and CrowdStrike (CRWD). Company Calendar Last Earnings11/04/2021Today10/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NLTX CIK1404644 Webwww.neoleukin.com Phone(866) 245-0312Fax778-331-4486Employees90Year Founded2019Profitability EPS (Trailing Twelve Months)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.22% Return on Assets-30.91% Debt Debt-to-Equity RatioN/A Current Ratio15.33 Quick Ratio15.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.08 per share Price / Book2.39Miscellaneous Outstanding Shares9,398,000Free Float9,250,000Market Cap$248.77 million OptionableNo Data Beta1.11 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:NLTX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
